BACKGROUND: CD3δ deficiency is a fatal form of severe combined immunodeficiency that can be cured by hematopoietic stem cell transplantation (HSCT). The presence of a thymus loaded with T-cell progenitors in patients with CD3δ deficiency may require special considerations in choosing the regimen of conditioning and the type of HSCT. OBJECTIVES: To study the outcome of CD3δ deficiency by using various modalities of stem cell transplantation. METHODS: We analyzed data on 13 patients with CD3δ deficiency who underwent HSCT in 7 centers. HSCT was performed by using different sources of donor stem cells as well as various conditioning regimens. RESULTS: One patient received stem cells from a matched related donor and survived after a second transplant, needing substantial conditioning in order to engraft. Only 2 of 7 other patients who received a mismatched related donor transplant survived; 2 of them had no conditioning, whereas the others received various combinations of conditioning regimens. Engraftment of T cells in the survivors appears incomplete. Three other patients who received stem cells from a matched unrelated donor survived and enjoyed full immune reconstitution. Two patients received unrelated cord blood without conditioning. One of them has had a partial but stable engraftment, whereas the other engrafted well but is only 12 months after HSCT. We also report here for the first time that patients with CD3δ deficiency can present with typical features of Omenn syndrome. CONCLUSIONS: HSCT is a successful treatment for patients with CD3δ deficiency. The small number of patients in this report prevents definitive statements on the importance of survival factors, but several are suggested: (1) HLA-matched donor transplants are associated with superior reconstitution and survival than are mismatched donor transplants; (2) substantial conditioning appears necessary; and (3) early diagnosis and absence of opportunistic infections may affect outcome. Copyright Â
BACKGROUND: CD3δ deficiency is a fatal form of severe combined immunodeficiency that can be cured by hematopoietic stem cell transplantation (HSCT). The presence of a thymus loaded with T-cell progenitors in patients with CD3δ deficiency may require special considerations in choosing the regimen of conditioning and the type of HSCT. OBJECTIVES: To study the outcome of CD3δ deficiency by using various modalities of stem cell transplantation. METHODS: We analyzed data on 13 patients with CD3δ deficiency who underwent HSCT in 7 centers. HSCT was performed by using different sources of donor stem cells as well as various conditioning regimens. RESULTS: One patient received stem cells from a matched related donor and survived after a second transplant, needing substantial conditioning in order to engraft. Only 2 of 7 other patients who received a mismatched related donor transplant survived; 2 of them had no conditioning, whereas the others received various combinations of conditioning regimens. Engraftment of T cells in the survivors appears incomplete. Three other patients who received stem cells from a matched unrelated donor survived and enjoyed full immune reconstitution. Two patients received unrelated cord blood without conditioning. One of them has had a partial but stable engraftment, whereas the other engrafted well but is only 12 months after HSCT. We also report here for the first time that patients with CD3δ deficiency can present with typical features of Omenn syndrome. CONCLUSIONS: HSCT is a successful treatment for patients with CD3δ deficiency. The small number of patients in this report prevents definitive statements on the importance of survival factors, but several are suggested: (1) HLA-matched donor transplants are associated with superior reconstitution and survival than are mismatched donor transplants; (2) substantial conditioning appears necessary; and (3) early diagnosis and absence of opportunistic infections may affect outcome. Copyright Â
Authors: Y Tsuji; K Imai; M Kajiwara; Y Aoki; T Isoda; D Tomizawa; M Imai; S Ito; H Maeda; Y Minegishi; H Ohkawa; J Yata; N Sasaki; K Kogawa; M Nagasawa; T Morio; S Nonoyama; S Mizutani Journal: Bone Marrow Transplant Date: 2006-03 Impact factor: 5.483
Authors: María J Recio; Miguel Angel Moreno-Pelayo; Sara S Kiliç; Alberto C Guardo; Ozden Sanal; Luis M Allende; Verónica Pérez-Flores; Angeles Mencía; Silvia Modamio-Høybjør; Elena Seoane; José R Regueiro Journal: J Immunol Date: 2007-02-15 Impact factor: 5.422
Authors: Corinne Antoine; Susanna Müller; Andrew Cant; Marina Cavazzana-Calvo; Paul Veys; Jaak Vossen; Anders Fasth; Carsten Heilmann; Nicolas Wulffraat; Reinhard Seger; Stéphane Blanche; Wilhelm Friedrich; Mario Abinun; Graham Davies; Robert Bredius; Ansgar Schulz; Paul Landais; Alain Fischer Journal: Lancet Date: 2003-02-15 Impact factor: 79.321
Authors: S Caillat-Zucman; F Le Deist; E Haddad; M Gannagé; L Dal Cortivo; N Jabado; S Hacein-Bey-Abina; S Blanche; J-L Casanova; A Fischer; M Cavazzana-Calvo Journal: Bone Marrow Transplant Date: 2004-06 Impact factor: 5.483
Authors: Gabrielle M Siegers; Mahima Swamy; Edgar Fernández-Malavé; Susana Minguet; Sylvia Rathmann; Alberto C Guardo; Verónica Pérez-Flores; Jose R Regueiro; Balbino Alarcón; Paul Fisch; Wolfgang W A Schamel Journal: J Exp Med Date: 2007-10-08 Impact factor: 14.307
Authors: Joel Sng; Burcu Ayoglu; Jeff W Chen; Jean-Nicolas Schickel; Elise M N Ferre; Salomé Glauzy; Neil Romberg; Manfred Hoenig; Charlotte Cunningham-Rundles; Paul J Utz; Michail S Lionakis; Eric Meffre Journal: Sci Immunol Date: 2019-04-12
Authors: Beatriz Garcillán; Ana V M Marin; Anaïs Jiménez-Reinoso; Alejandro C Briones; Miguel Muñoz-Ruiz; María J García-León; Juana Gil; Luis M Allende; Eduardo Martínez-Naves; María L Toribio; José R Regueiro Journal: Front Immunol Date: 2015-01-29 Impact factor: 7.561